Signaling Pathways and Emerging Therapies in Multiple Myeloma

Vijay Ramakrishnan, Anita D’Souza

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In the absence of a single unifying genetic event contributing to disease manifestation, efforts have focused on understanding signaling events deregulated in myeloma plasma cells. MM cells are dependent on both cellular and non-cellular components of the tumor microenvironment such as bone marrow stromal cells, endothelial cells, and cytokines such as interleukin 6 (IL6), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) for their growth and survival. The cumulative effect of such interactions is the aberrant activation of numerous signal transduction pathways within the MM plasma cells leading to uncontrolled growth and prevention of apoptosis. Here, we will review our current understanding of some of the key signal transduction pathways dysregulated in MM and emerging therapies targeting these pathways in MM.

Original languageEnglish (US)
Pages (from-to)156-164
Number of pages9
JournalCurrent Hematologic Malignancy Reports
Volume11
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Multiple Myeloma
Plasma Cells
Signal Transduction
Therapeutics
Antibody-Producing Cells
Tumor Microenvironment
Somatomedins
Growth
Mesenchymal Stromal Cells
Vascular Endothelial Growth Factor A
Interleukin-6
Endothelial Cells
Apoptosis
Cytokines
Neoplasms

Keywords

  • Akt
  • mTOR
  • Multiple myeloma
  • NF-κB
  • Signaling
  • Signaling inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Signaling Pathways and Emerging Therapies in Multiple Myeloma. / Ramakrishnan, Vijay; D’Souza, Anita.

In: Current Hematologic Malignancy Reports, Vol. 11, No. 2, 01.04.2016, p. 156-164.

Research output: Contribution to journalReview article

@article{fa6bf4d95f034d24a9bad73b626e30a6,
title = "Signaling Pathways and Emerging Therapies in Multiple Myeloma",
abstract = "Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In the absence of a single unifying genetic event contributing to disease manifestation, efforts have focused on understanding signaling events deregulated in myeloma plasma cells. MM cells are dependent on both cellular and non-cellular components of the tumor microenvironment such as bone marrow stromal cells, endothelial cells, and cytokines such as interleukin 6 (IL6), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) for their growth and survival. The cumulative effect of such interactions is the aberrant activation of numerous signal transduction pathways within the MM plasma cells leading to uncontrolled growth and prevention of apoptosis. Here, we will review our current understanding of some of the key signal transduction pathways dysregulated in MM and emerging therapies targeting these pathways in MM.",
keywords = "Akt, mTOR, Multiple myeloma, NF-κB, Signaling, Signaling inhibitors",
author = "Vijay Ramakrishnan and Anita D’Souza",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s11899-016-0315-4",
language = "English (US)",
volume = "11",
pages = "156--164",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Signaling Pathways and Emerging Therapies in Multiple Myeloma

AU - Ramakrishnan, Vijay

AU - D’Souza, Anita

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In the absence of a single unifying genetic event contributing to disease manifestation, efforts have focused on understanding signaling events deregulated in myeloma plasma cells. MM cells are dependent on both cellular and non-cellular components of the tumor microenvironment such as bone marrow stromal cells, endothelial cells, and cytokines such as interleukin 6 (IL6), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) for their growth and survival. The cumulative effect of such interactions is the aberrant activation of numerous signal transduction pathways within the MM plasma cells leading to uncontrolled growth and prevention of apoptosis. Here, we will review our current understanding of some of the key signal transduction pathways dysregulated in MM and emerging therapies targeting these pathways in MM.

AB - Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In the absence of a single unifying genetic event contributing to disease manifestation, efforts have focused on understanding signaling events deregulated in myeloma plasma cells. MM cells are dependent on both cellular and non-cellular components of the tumor microenvironment such as bone marrow stromal cells, endothelial cells, and cytokines such as interleukin 6 (IL6), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) for their growth and survival. The cumulative effect of such interactions is the aberrant activation of numerous signal transduction pathways within the MM plasma cells leading to uncontrolled growth and prevention of apoptosis. Here, we will review our current understanding of some of the key signal transduction pathways dysregulated in MM and emerging therapies targeting these pathways in MM.

KW - Akt

KW - mTOR

KW - Multiple myeloma

KW - NF-κB

KW - Signaling

KW - Signaling inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84962224784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962224784&partnerID=8YFLogxK

U2 - 10.1007/s11899-016-0315-4

DO - 10.1007/s11899-016-0315-4

M3 - Review article

C2 - 26922744

AN - SCOPUS:84962224784

VL - 11

SP - 156

EP - 164

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -